GlassScriptPhysician profile
Eric D Harding
NPI 1942203286
$1,388.91
in general payments reported to CMS, 2019-2025
23 companies · $151 in 2025
The $151 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.74 · 2020: $84.02 · 2021: $126 · 2022: $216 · 2023: $217 · 2024: $497 · 2025: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $864.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $258.32 | 2024 | Inspire |
| Abbvie INC. | $242.82 | 2021-2025 | |
| Amgen INC. | $141.77 | 2019-2025 | Otezla, Repatha, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $94.99 | 2020-2023 | Vyvanse |
| Pfizer INC. | $93.51 | 2019-2025 | |
| Glaxosmithkline, LLC. | $73.56 | 2023-2025 | Pediarix, Bexsero, Rotarix |
| Sanofi Pasteur INC. | $65.84 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $56.99 | 2022-2025 | Vaxneuvance, Gardasil 9, M-M-R II |
| Supernus Pharmaceuticals, INC. | $52.90 | 2023-2025 | Qelbree, Qelbree |
| Astellas Pharma US INC | $45.93 | 2023-2024 | Veozah |
| Ironwood Pharmaceuticals, INC | $36.05 | 2024 | |
| Vbi Vaccine (Delaware) INC. | $33.17 | 2022 | |
| Allergan, INC. | $28.26 | 2020-2022 | |
| Shire North American Group INC | $25.86 | 2019 | |
| Boston Scientific Corporation | $24.23 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $18.44 | 2023 | Azstarys |
| Tris Pharma INC | $17.50 | 2021 | |
| Heartflow, INC. | $14.81 | 2024 | |
| Lilly USA, LLC | $14.67 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.64 | 2020 | |
| Celgene Corporation | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.